Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-22
2008-01-22
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
10773073
ABSTRACT:
The invention relates to the use of a compound of formula (I):for the preparation of pharmaceutical compositions for increasing the circulating, cellular and extracellular levels of TGF-β1.
REFERENCES:
patent: 4521428 (1985-06-01), Nisato et al.
patent: 5229389 (1993-07-01), Coude et al.
patent: 5270320 (1993-12-01), Coude et al.
patent: 5281606 (1994-01-01), Guzzi et al.
patent: 5292745 (1994-03-01), Heaulme et al.
patent: 5462945 (1995-10-01), Guzzi et al.
patent: 5468753 (1995-11-01), Coude et al.
patent: 5618822 (1997-04-01), Guzzi et al.
patent: 5981754 (1999-11-01), Badoni et al.
patent: 6034090 (2000-03-01), Baroni et al.
patent: 6342505 (2002-01-01), Bono-Combie et al.
patent: 101381 (1984-02-01), None
patent: 0458696 (1991-11-01), None
patent: 0458697 (1991-11-01), None
patent: 0498718 (1992-08-01), None
patent: 0645755 (1995-03-01), None
patent: WO 93/11107 (1993-06-01), None
patent: WO 96/21449 (1996-07-01), None
patent: WO 97/01536 (1997-01-01), None
Tashiro et al., Differential Expression of Transforming Growth Factor-β Isoforms in Human Prion Diseases, Neuropath. Appl. Neuro., 24:284-292 (1998).
The Center for Healthy Aging's Helpguide online at http://www.helpguide.org/elder/creutzfeldt—jakob.htm.
J. H. Prehn, Medline Abstract No. 96226070.
J. P. Terranova, Medline Abstract No. 97011603.
J. Mathieu, Medline Abstract No. 97112057.
Derwent Patent Abstract No. 199709.
Boche et al., TGFBeta1 regulates the inflammatory response during chronic neurodegeneration, Neurobiology of Disease, vol. 22, 2006, pp. 638-650.
Cunningham et al., Transforming growth factor Beta1, the dominant cytokine in murine prion disease: influence on inflammatory cytokine synthesis and alteration of vascular extracellular matrix, Neuropathology and Applied Neurobiology, vol. 28, 2002, pp. 107-119.
Kempster et al., Time of transforming growth factor beta 1 inoculation alters the incubation of BSE in mice, Neuroreport, vol. 15, No. 14, Oct. 2004, pp. 2233-2236.
Bono-Combie Françoise
Fournier Jacqueline
Guzzi Umberto
Herbert Jean Marc
Lamarche Isabelle
Krupen Karen I.
Morris Patricia L.
sanofi-aventis
LandOfFree
Use of 4-substituted tetrahydropyridines for the manufacture... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 4-substituted tetrahydropyridines for the manufacture..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 4-substituted tetrahydropyridines for the manufacture... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3908513